Prosensa receives securities class action lawsuit

A law office recently noted that it filed a securities class action lawsuit against a pharmaceutical developer due to issues with the company's initial public offering.

The Rosen Law Firm announced that the litigation was filed against Prosensa Holding, NV. This includes all shareholders who acquired interests from the company's initial public offering on June 28, 2013.

Allegations center around the company's leaders potentially violating federal securities laws. This is due to the registration statement having a number of details that may have been false or misleading about the company's drug drisapersen, as well as its Phase II and III clinical studies. There were also details about the drug's regulatory approval that may not have been accurate.

Shareholders have the option to take up the lead plaintiff position in the case, as there has yet to be a certified class determined. This position will require an application to the court, and these individuals will need to be approved by the court as adequate class representatives. All interested parties need to file all necessary paperwork by Sept. 16, 2014.

For those who took part in the IPO and would like to learn more about the process, the lead plaintiff position or the case itself, the law office has some contacts waiting to discuss these matters. Kevin Chan and Phillip Kim can be reached by telephone or email. There are also further details on the law firm's website.

Second lawsuit filed
Another law office explained that it also filed litigation against the company related to shareholders who questioned its IPO during the middle of last year.

The Law Offices of Howard G. Smith noted that the class action lawsuit was filed against Prosensa Holding in the U.S. District Court for the Southern District of New York. This lawsuit will deal with many of the aforementioned issues related to the IPO, including the company's comments about drisapersen. The registration statement may not only have contained false or misleading information about the drug, but there also were details that may have been left out of the statement, overall.

It is also an option to discuss these matters with this litigation firm. Howard Smith is the best person to speak with, and he is available by email or telephone. Additional information can be obtained by visiting the law office's website.